Pharmaceuticals

Vensica Medical gets FDA clearance for a Phase 2 study of its ultrasound device that delivers botulinum toxin without needles for overactive bladder.

A new HHS agenda reopens the door for controversial peptides, just as a wave of next-gen obesity drugs threatens to upend the entire market.

Kiniksa raises its 2026 ARCALYST forecast after a blowout quarter, using its financial strength to advance a pipeline aimed at redefining pericarditis care.

With a massive Series A, Coultreon Biopharma is advancing a novel SIK3 inhibitor spun out of Galapagos to rival injectable blockbusters for autoimmune disease.

BRC Therapeutics gets the FDA green light for BRC-002, a novel cannabinoid drug for CRPS, a severe pain condition with no approved US treatments.

Pharma manufacturer Mikart cuts the ribbon on a new Atlanta HQ while boosting bottling capacity by 50%, tackling industry demand and fueling local growth.

A new partnership between insurer Chubb and tech firm VCT introduces a proactive approach to prevent trial risks, enhancing patient safety and data integrity.

A new collaboration aims to merge drugs with AI-driven apps, creating a novel class of therapy that could revolutionize treatment, starting with rare cancers.

With gonorrhea becoming increasingly resistant to antibiotics, a new $2.6M grant fuels the development of a promising preventative vaccine platform.

Umoja Biopharma's UB-VV500 aims to revolutionize myeloma care by creating a dual-antigen CAR T therapy directly inside the patient's body.

New Phase 2a data reveals Oruka Therapeutics' ORKA-001 achieved complete skin clearance in nearly two-thirds of patients, positioning it as a potential game-changer.

A new report reveals payers are rewriting drug benefit rules, sacrificing rebates for more control as they grapple with the high cost of new therapies.

With investments exceeding $1B, PCI Pharma Services is expanding its US sterile manufacturing, tackling supply chain risks and boosting domestic production.

Once a student finding refuge at Milton Hershey School, Maria Trinh Kraus now chairs its boards, shaping the very legacy that transformed her own life.

A new partnership brings a single-dose treatment for common, serious infections to Sub-Saharan Africa, a region with high prevalence and unmet medical needs.

A major trial shows once-weekly rezafungin is as effective as daily drugs for preventing deadly fungal infections, heralding a new era for patient care.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

A landmark study reveals essential phospholipids significantly reduce liver fat and fatigue in MASLD patients, offering a new tool against a silent epidemic.

A Cambridge firm's novel intracoronary liquid biopsy is creating a high-resolution data map of heart disease, promising a new era of precision medicine.

By emphasizing deep anatomical knowledge, Medytox aims to elevate industry standards and solidify its leadership in Asia's booming medical aesthetics market.